We, therefore, aimed to describe the expression of three CTAs, PRAME, NY-ESO-1, and SSX2, and analyze their prognostic value in a large cohort of high-risk soft tissue sarcomas with long-term follow-up. The gene discussed is SSX2; the disease is soft tissue sarcoma.